14/04/2026
I am pleased to announce a new collaboration with DATAVISYN, a leading visual data science company based in my hometown of Linz, Austria, focused on enabling discovery in biopharmaceutical R&D.
In many R&D organizations, critical decisions are still slowed down by fragmented data, disconnected evidence sources, and workflows that are difficult to reproduce or explain.
datavisyn addresses this challenge with a suite of interactive platforms—Ordino and Aevidence—that bring together complex biological and chemical data and curated scientific evidence into a single, intuitive workflow. This enables research teams to explore, prioritize, and validate targets in a more integrated, transparent, and ultimately faster way. Backbone of our products is a unique curated database of public data from 80+ biological, compound, drug, and disease-specific repositories.
What I find particularly compelling is the emphasis on traceability and usability: analyses can be reproduced, shared, and revisited, moving beyond fragmented workflows and disconnected tools, and towards decisions that are both data-driven and explainable.
In my role as Business Development Partner at datavisyn, I bring a combination of scientific, strategic, and analytical experience, from a PhD in molecular biology and early R&D work to many years in insights and strategy in pharma, complemented by a strong focus on data science, analytics, and data visualization. I have always seen data visualization as both an art and a science—critical for turning complexity into clarity.
My focus will be on supporting biopharma and biotech companies in Switzerland, leveraging my network across R&D to connect datavisyn’s capabilities to concrete, high-impact use cases in discovery and translational research.
If you are currently working through challenges around target prioritization, evidence integration, or decision traceability in R&D, I would be glad to connect and arrange a short discussion or demonstration.
